Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) to select the optimal patients for matched therapy?
about
Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) to select the optimal patients for matched therapy?
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Challenges and future of bioma ...... patients for matched therapy?
@en
Challenges and future of bioma ...... e rely on immunohistochemistry
@nl
type
label
Challenges and future of bioma ...... patients for matched therapy?
@en
Challenges and future of bioma ...... e rely on immunohistochemistry
@nl
prefLabel
Challenges and future of bioma ...... patients for matched therapy?
@en
Challenges and future of bioma ...... e rely on immunohistochemistry
@nl
P2093
P2860
P356
P1433
P1476
Challenges and future of bioma ...... patients for matched therapy?
@en
P2093
Ari Rosenberg
Ayush Arya
Derek A Wainwright
Hiral Shah
Kirtee Raparia
Lauren Chiec
Massimo Cristofanilli
Sandip Patel
Victoria Villaflor
Young Kwang Chae
P2860
P304
100863-100898
P356
10.18632/ONCOTARGET.19809
P407
P577
2017-08-01T00:00:00Z